(PDF) P1.09-12 Simultaneous Platform of Genotyping EGFR,

P1.09-12 Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients With NSCLC Highlights Correlation of ROS1 and PD-L1 Expression

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.788

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.17-01 PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients From Brazil

Journal of Thoracic Oncology

Respiratory Medicine

English

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.09-06 the Incidence of PD-L1 in NSCLC and Its Correlation With Driver Mutations in Turkish Patients; A Single Center Experience

Journal of Thoracic Oncology

Respiratory Medicine

English

ROS1 Rearrangements Are Only Found in Lung Adenocarcinomas With Diffuse Strong IHC Expression of ROS1

Forensic Medicine

English

Ceritinib Beim ROS1-positiven NSCLC

Im Focus Onkologie

English

P2.09-13 Correlation of ROS1 (SP384) Immunohistochemistry With ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization

Journal of Thoracic Oncology

Respiratory Medicine

English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice

English